OLIGOMETASTATIC PROSTATE CARCINOMA
Clinical trials for OLIGOMETASTATIC PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OLIGOMETASTATIC PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for OLIGOMETASTATIC PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread and is no longer responding to standard treatments. The drug delivers a radioactive payload directly to cancer cells that have a specific marker (PSMA). The study…
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New combo therapy aims to halt spread of prostate cancer
Disease control OngoingThis study tests whether adding the drug relugolix to standard radiation therapy can slow the spread of prostate cancer that has spread to a few other parts of the body. Relugolix lowers testosterone, which can help stop cancer growth. About 194 men with this type of prostate can…
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Shorter radiation course tested for prostate cancer spread
Disease control OngoingThis study is testing whether a shorter, more intense course of radiation has fewer side effects for men whose prostate cancer has returned and spread to a few lymph nodes. It compares two radiation methods: proton beam therapy and standard IMRT. The main goal is to see which app…
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC